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Materials and Methods: From 1993 to 2007, 953 patients (median age 
65 years) underwent ADV (n=685) or SALV (n=268) RT with non 
conformal (n=169), 3DCRT (n=658) or IMRT (n=20) technique at 1.80 
Gy/fraction, at a median RT dose of 70.2 Gy, or moderately 
hypofractionated (median 28 fractions) Tomotherapy (n=106) to a 
median 2-Gy equivalent (EQD2, a/b=3) dose of 70 Gy. WPRT was 
delivered to 282 patients at a median of 50 Gy. The median follow-up 
(FU) of pts treated with prostatic bed (PB) only RT was longer (110 vs 
85 months) as compared to the WPRT+PB group.  
Results: After a median FU of 103 months, actuarial 10-year overall 
survival (OS) was 86%. A 2ndNPL arose in 101 patients after a median 
of 46 months from RT (44/101 after >5 years). Thirty-two were 
INFIELD and 69 were OUTFIELD. The 10-year overall risk of 2ndNPL 
was 14% vs 9% (p=0.10) for pts receiving PB only or WPRT+PB, 
respectively (4% vs 2%, p=0.17, for INFIELD and 9% vs 6%, p=0.33, for 
OUTFIELD). Of note, the 10-year risk of 2ndNPL was significantly 
higher (17% vs 11%, p=0.02) in patients experiencing any (acute or 
late) GU toxicity Grade ≥2. Multivariate analysis, which indicated the 
independent predictive role of age >65 year in all subgroups, 
confirmed Grade ≥2 GU toxicity as a significant predictor of the risk of 
overall (HR 2.15, p=0.04) and OUTFIELD (HR 2.10, p=0.04), but not 
INFIELD 2ndNPL. When the analysis was limited to 2ndNPL onset after 
>5 year from RT, diabetes emerged as the only independent predictor 
of overall 2ndNPL (HR 2.19, p=0.048) and age >65 that of OUTFIELD 
ones (HR 1.08, p=0.02), while no factors independently predicted 
INFIELD 2ndNPL (n=13). Overall, 123 pts died, 53 owing to PCa 
progression, 34 to a 2ndNPL and 36 to non neoplastic causes. The 10-
year risk of death was quite similar in pts experiencing a clinical 
relapse of PCa or an INFIELD or OUTFIELD 2ndNPL (40% vs 31% vs 37%, 
respectively, p=0.48) and significantly higher than that (6%) of pts 
bNEDs or with a PSA failure only after RT. Importantly, no role 
emerged for RT dose, technique or fractionation. 
Conclusions: Although preliminary, this study suggests that the 
impact of treating larger volumes with WPRT may be not significant, 
in contrast with the hypothesis of a proportionally higher incidence of 
2ndNPL with the increase of body integral dose. The correlation which 
emerged between GU toxicity and the risk of 2ndNPL deserves further 
investigation.  
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Purpose/Objective: Purpose of this study is to analyze outcomes and 
pre-treatment prognostic factors in high-risk prostate cancer patients 
with initial PSA > 20 ng/mL, treated with high-dose External-Beam 
Radiotherapy (EBRT) and androgen-deprivation therapy (ADT) in a 
single institution. 
Materials and Methods: Between March 2003 and December 2011, 155 
consecutive high-risk prostate cancer patients a) presenting with 
pretreatment PSA level > 20 ng/mL, b) treated with definitive EBRT 
and c) with a minimum follow-up of 24 months were included in this 
retrospective analysis. Phoenix definition was used to define 
biochemical control. Multivariate analysis was performed to 
determine the independent prognostic impact of pre-treatment 
clinical factors (T stage, PSA and Gleason Score [GS]) on clinical 
outcomes (biochemical Disease-Free Survival [bDFS], Distant 
Metastasis Free Survival [DMFS], Cancer-Specific Survival [CSS], 
Overall Survival [OS]). 
Results:  
 
At a median follow-up of 62 months, actuarial bDFS, DMFS, CSS and OS 
at 5 years were 64.8%, 85.2%, 95.8%, and 94.4%, respectively. On 
multivariate analysis, only GS was significantly associated with three 
clinical endpoints (bDFS: HR 1.6; p=0.022, CSS: HR 4.27, p=0.044, OS: 
HR 2.6;p=0.038). Pre-treatment zenith PSA (zPSA) was associated only 
with bDFS (HR 1.87; p=0.027). 
Conclusions: Patients with 'high' PSAl evels (>20 ng/mL) or 'ultra-high' 
PSA levels (> 50 ng/mL) showed favorable clinical outcomes, 
supporting thus the role of local radiotherapy as primary therapy in 
combination with long-term ADT in patients with high PSA levels at 
diagnosis. As GS of 8-10 resulted to be the strongest predictor of 
outcome, a subgroup of patients at worse prognosis might be early 
identified, since these patients represent the ideal candidates for 
more tailored and aggressive therapies in future trials. 
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Purpose/Objective: Neo-adjuvant chemotherapy (nCT) has known 
survival benefit in the treatment of MIBC. Favourable response is 
associated with improved outcome and identifies those who may 
benefit from bladder preservation with radical radiotherapy. 
Conventionally response assessment is with cystoscopy. We report on 
the use of DW-MRI as a potential non-invasive alternative means of 
assessment and as a predictor of nCT sensitivity.  
Materials and Methods: 19 patients with confirmed MIBC suitable for 
nCT were recruited prospectively to an ethics approved protocol. DW-
MRI was performed on a 1.5T system using b-values 0,50,100,250,500 
and 750s/mm2 prior to and on completion of nCT. Tumour was drawn 
on the 750s/mm2 image and transferred onto the corresponding ADC 
map to record mean values. Following final DW-MRI patients 
proceeded to cystoscopy + biopsy. Association between nCT 
sensitivity, pre-treatment ADC, post-treatment ADC and change of 
ADC (ΔADC) was analysed. 
Results: 12 patients achieved pathological complete response, 6 
achieved partial response and 1 progressed following nCT (as assessed 
on cystoscopy and T2-weighted MRI). In 15 patients tumour was 
identified on pre-nCT DW-image. 4 patients had no measurable 
disease on pre-nCT MRI. Baseline tumour median ADC was 1.3x10-
3mm2/s (range 0.7-2.7x10-3mm2/s). 
Complete response was associated with a significant increase in 
median ADC from 1.3x10-3mm2/s (range 0.7-2.7x10-3mm2/s) to 2.2x10-
3mm2/s (range 1.9-3.2x10-3mm2/s) (p=0.036). Change in mean ΔADC 
was significantly greater in complete responders compared to 
incomplete responders; responders median ΔADC 1.1x10-3 mm2/s, 
range 0.6-1.41x10-3mm2/s; incomplete responders median ΔADC 
0.1x10-3mm2/s, range 0.03-0.3x10-3mm2/s (p=0.034). 
Pre-treatment ADC was not predictive of response to nCT.  
